These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 34128042)
1. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan. Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales. Bullement A; Underhill S; Fougeray R; Hatswell AJ Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922 [TBL] [Abstract][Full Text] [Related]
3. Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan. Kashiwa M; Matsushita R Clin Ther; 2020 Jul; 42(7):1376-1387. PubMed ID: 32653227 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer. Zhou K; Zhou J; Zhang M; Liao W; Li Q Clin Transl Oncol; 2020 Mar; 22(3):337-343. PubMed ID: 31041716 [TBL] [Abstract][Full Text] [Related]
5. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Alsina M; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Hosokawa A; Yalçın Ş; Fujitani K; Beretta GD; Cutsem EV; Winkler RE; Makris L; Ilson DH; Tabernero J Lancet Oncol; 2018 Nov; 19(11):1437-1448. PubMed ID: 30355453 [TBL] [Abstract][Full Text] [Related]
6. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A; Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618 [TBL] [Abstract][Full Text] [Related]
7. A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Hamerton L; Gomes K; Fougeray R; Hook ES; Gomes MV; Hauch O; Bullement A Future Oncol; 2023 Mar; 19(9):643-650. PubMed ID: 37115022 [No Abstract] [Full Text] [Related]
8. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856 [TBL] [Abstract][Full Text] [Related]
9. [Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy]. Hamada S; Komatsu S; Shibata R; Konishi T; Matsubara D; Soga K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y Gan To Kagaku Ryoho; 2020 Dec; 47(13):2056-2058. PubMed ID: 33468799 [TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective. Chan BM; Hochster HS; Lenz HJ Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848 [TBL] [Abstract][Full Text] [Related]
11. Trifluridine/tipiracil for the treatment of metastatic gastric cancer. Kawazoe A; Shitara K Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):65-70. PubMed ID: 31920125 [No Abstract] [Full Text] [Related]
12. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. Tabernero J; Alsina M; Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Ando T; Yalçın Ş; Van Cutsem E; Sabater J; Skanji D; Leger C; Amellal N; Ilson DH Gastric Cancer; 2020 Jul; 23(4):689-698. PubMed ID: 32128634 [TBL] [Abstract][Full Text] [Related]
13. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS). Shitara K; George B; Taieb J; Sundar R; Fakih MG; Makris L; Benhadji KA; Ghidini M J Cancer Res Clin Oncol; 2023 Sep; 149(11):9361-9374. PubMed ID: 37213030 [TBL] [Abstract][Full Text] [Related]
14. Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. Giuliani J Clin Colorectal Cancer; 2022 Jun; 21(2):e145-e147. PubMed ID: 34969632 [TBL] [Abstract][Full Text] [Related]
15. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902 [TBL] [Abstract][Full Text] [Related]
16. The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer: A protocol for systematic review and meta-analysis. He X; Zhang T; Wu L; Wu Y; Zhou X Medicine (Baltimore); 2021 Jan; 100(2):e24110. PubMed ID: 33466182 [TBL] [Abstract][Full Text] [Related]
17. Trifluridine/tipiracil in the treatment of gastric cancer. Fostea RM; Arkenau HT Future Oncol; 2022 Apr; 18(12):1511-1517. PubMed ID: 35081748 [TBL] [Abstract][Full Text] [Related]
18. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer. Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718 [TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. Bachet JB; Wyrwicz L; Price T; Cremolini C; Phelip JM; Portales F; Ozet A; Cicin I; Atlan D; Becquart M; Vidot L; Mounedji N; Van Cutsem E; Taieb J; Falcone A ESMO Open; 2020 Jun; 5(3):e000698. PubMed ID: 32487542 [TBL] [Abstract][Full Text] [Related]
20. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer. Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]